Today: 21 May 2026
Salesforce stock gets new Goldman Buy call — here’s the next catalyst for CRM
12 January 2026
1 min read

Salesforce stock gets new Goldman Buy call — here’s the next catalyst for CRM

New York, Jan 12, 2026, 14:15 EST — Regular session

  • Shares tick higher in afternoon trading after Goldman Sachs kicks off coverage with a Buy rating and $330 price target
  • Goldman highlights “AI adoption” as a key demand driver; investors await clearer signs of Agentforce revenue growth
  • Salesforce will present at the J.P. Morgan Healthcare Conference on Jan. 13

Salesforce shares nudged higher Monday after Goldman Sachs analyst Gabriela Borges initiated coverage with a Buy rating and set a $330 price target. Borges highlighted AI adoption as a “positive tailwind” for software demand. The stock climbed 0.3% to $260.76 in mid-afternoon trading in New York. TipRanks

The call comes as investors seek solid proof that Salesforce can convert Agentforce—its AI-driven task automation initiative—into accelerated subscription growth, rather than just generating demos and pilots.

A major Wall Street bank’s fresh coverage can move a stock like Salesforce, given the crowded positioning where even slight shifts in sentiment can trigger flows. This update comes just before the company’s appearance at a key investor conference this week.

Goldman, in a note flagged by Investing.com, estimates Agentforce could boost Salesforce’s “Platform and Other” revenue by about 4% over the next 12 to 18 months, potentially sparking a revenue inflection as soon as 2026. However, the bank also warns that gains might be partly offset by continued share declines in Commerce and Marketing Cloud. Investing.com

The broader market held steady as the S&P 500-linked SPY ETF gained roughly 0.2%, with the tech-focused QQQ matching that rise. ServiceNow edged up 0.8%, while Oracle jumped 3.3%.

Salesforce is pushing growth by doubling down on AI and data tools. In its December quarter, the company boosted its full-year revenue forecast to between $41.45 billion and $41.55 billion. Meanwhile, Agentforce and Data 360 annual recurring revenue — a key subscription metric — hit nearly $1.4 billion, soaring 114% from the previous year.

The next key event is Tuesday, when Salesforce President of Sales Mark Sullivan will speak at the J.P. Morgan Healthcare Conference at 2:15 p.m. PT, per the company’s events calendar.

Salesforce hasn’t set a date for its upcoming earnings release yet, though Nasdaq’s earnings calendar pegs it around Feb. 25. That report usually offers a key look at whether new products are beginning to boost billings and guidance.

The AI trade can shift fast. If customers drag their feet moving from trials to full rollouts — or if competitors snag deals through better pricing or integration — revenue growth might fall short, despite optimistic research notes.

Monday’s shift was modest. Attention now turns to Tuesday’s conference remarks for signals on demand in a crucial industry segment, followed by the upcoming earnings report later this quarter to gauge 2026 momentum more clearly.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Harmony Gold stock jumps nearly 10% as gold cracks $4,600; CPI looms for HMY
Previous Story

Harmony Gold stock jumps nearly 10% as gold cracks $4,600; CPI looms for HMY

Lululemon stock rises after holiday-quarter outlook shifts to high end as LULU investors eye ICR
Next Story

Lululemon stock rises after holiday-quarter outlook shifts to high end as LULU investors eye ICR

Go toTop